Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study
ANZ Journal of Surgery · 2026-10 · 96 (10) · 3116-3125
DOI: 10.1111/ans.70961 ↗Kurz gefasst
Fachartikel in der Zeitschrift ANZ Journal of Surgery, online erschienen am 09.09.2026. Verfasst von Salil Dutt Barrett und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Splenectomy, Elective Surgical Procedures, Hematologic Diseases. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Splenectomy has traditionally been used to treat a range of haematological diseases. Advances in medical therapies and minimally invasive surgery have altered its therapeutic role. This study evaluates evolving indications and outcomes of elective splenectomy in an Australian teaching hospital over a 27‐year period.
Methods
Adult patients undergoing elective splenectomy for haematological disease between 1999 and 2025 at a single tertiary institution were identified from medical records. Caseload, demographics, operative approach, complications and follow‐up outcomes were assessed either annually or over three 9‐year cohorts. Regression and Fisher's exact tests were used for trend analysis.
Results
Seventy patients underwent splenectomy. The annualised caseload and cohort patient age decreased significantly over the study period ( p = 0.005 and 0.020, respectively). Benign indications accounted for 54% of patients, most commonly immune thrombocytopenia, while lymphoma and myelofibrosis predominated among malignant indications. There was an upward trend for laparoscopic splenectomy over time ( p = 0.051), reduced conversion rates ( p = 0.189) and a decrease in operative time ( p = 0.012). The overall post‐operative complication rate was 21.4%, and most were minor. Ninety‐day post‐operative mortality was zero. The median follow‐up was 9.1 years. Long‐term survival was primarily influenced by underlying haematologic disease, with most long‐term survivors well with normal platelet counts.
Conclusion
Despite declining referrals in the era of targeted therapies, splenectomy remains a safe and effective treatment option in selected patients. Outcomes are favourable when performed laparoscopically in experienced hands, and long‐term follow‐up demonstrates sustained haematologic benefit in surviving patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
- Upper Gastrointestinal Surgical Unit, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
- Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
ORCID-Profile: Salil Dutt Barrett, Anthony Downhill, Douglas Greer, Ian Kerridge, Chris Ward, Matthew Greenwood, Thomas J Hugh
Zitieren
APA
Barrett, S. D., Downhill, A., Greer, D., Stevenson, W., Kerridge, I., Ward, C., Greenwood, M., Mackinlay, N., Coyle, L., & Hugh, T. J. (2026). Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study. ANZ Journal of Surgery, 96(10), 3116-3125. https://doi.org/10.1111/ans.70961
Vancouver
Barrett SD, Downhill A, Greer D, Stevenson W, Kerridge I, Ward C, et al. Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study. ANZ Journal of Surgery. 2026;96(10):3116-3125. doi:10.1111/ans.70961
BibTeX
@article{Barrett2026,
author = {Barrett, Salil Dutt and Downhill, Anthony and Greer, Douglas and Stevenson, William and Kerridge, Ian and Ward, Chris and Greenwood, Matthew and Mackinlay, Naomi and Coyle, Luke and Hugh, Thomas J},
title = {Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study},
journal = {ANZ Journal of Surgery},
year = {2026},
volume = {96},
number = {10},
pages = {3116--3125},
doi = {10.1111/ans.70961}
}
EUVIMED